Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) Users: Preliminary Observations

Archives of General Psychiatry

Volumn 46, Issue 1, 1989, Pages 20-22

  Price, Lawrence H ^a   Ricaurte, George A ^b   Krystal, John H ^a   Heninger, George R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PROLACTIN; TRYPTOPHAN;

ADULT; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOOD; NEUROTOXICITY; PRIORITY JOURNAL;

3,4-METHYLENEDIOXYAMPHETAMINE; ADULT; AFFECT; AMPHETAMINES; DESIGNER DRUGS; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROLACTIN; SEROTONIN; SUBSTANCE-RELATED DISORDERS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRYPTOPHAN;

EID: 0024558968     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1989.01810010022003     Document Type: Article

References (16)

1. Stone DM, Stahl DC, Hanson GR, Gibb JW: The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128:41-48.
2. Battaglia G, Yeh SY, O'Hearn, Molliver ME, Kuhar MJ, DeSouza EB: 3,4Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: Quantification of neurodegeneration by measurement of [3H] paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-916.
3. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS: Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-345.
4. Mokler DJ, Robinson SE, Rosecrans JA: (±) 3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats. Eur J Pharmacol 1987;138:265-268.
5. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987;240:1-7.
6. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW: (±) 3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988;260:51-55
7. Ricaurte GA, DeLanney LE, Irwin I, Langston JW: Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res 1988;446:165-168.
8. Peroutka SJ: Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) on an undergraduate campus. N Engl J Med 1987;317:1542-1543.
9. Greer G, Tolbert R: Subjective reports on the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319-327.
10. Peroutka SJ, Pascoe N, Faull KF: Monoamine metabolites in the cerebrospinal fluid of recreational users of 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’). Res Commun Drug Abuse 1987;8:125-138.
11. Charney DS, Heninger GR, Reinhard JF Jr, Sternberg DE, Hafstead KM: The effect of IV L-tryptophan on prolactin, growth hormone, and mood in healthy subjects. Psychopharmacology 1982;78:38-43.
12. Heninger GR, Charney DS, Sternberg DE: Serotonergic function in depression: Prolactin response to intravenous tryptophan in depressed patients and healthy subjects. Arch Gen Psychiatry 1984;41:398-402.
13. Meltzer HY, Lowy MT: The serotonin hypothesis of depression, in Meltzer HY (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987, pp 513-526.
14. Price LH, Charney DS, Delgado PL, Heninger GR: Lithium treatment and serotonergic function: Neuroendocrine and behavioral responses to intravenous L-tryptophan in affective disorder patients. Arch Gen Psychiatry 1989;46:13-19.
15. Delgado PL, Charney DS, Price LH, Anderson G, Landis H, Heninger GR: Dietary tryptophan restriction produces an upregulation of the neuroendocrine response to infused tryptophan in healthy subjects. Soc Neurosci Abstr 1987;13:227.
16. McCann SM: Lumpkin MD, Mizunuma H, Khorram O, Ottlecz A, Samson WK: Peptidergic and dopaminergic control of prolactin release. Trends Neurosci 1984;5:127-131.